[ CAS No. 26456-59-7 ] {[proInfo.proName]}

Name: 26456-59-7|Pyrimidin-5-ol|98%
Brand: Ambeed
SKU: A529026
Price: 20.0 USD
Availability: InStock
Rating: 99 (28 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 26456-59-7 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 26456-59-7 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 26456-59-7 ]

SDS Specification

Alternatived Products of [ 26456-59-7 ]

Product Details of [ 26456-59-7 ]

CAS No. :	26456-59-7	MDL No. :	MFCD06412562
Formula :	C₄H₄N₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	LTXJLQINBYSQFU-UHFFFAOYSA-N
M.W :	96.09	Pubchem ID :	565855
Synonyms :

Calculated chemistry of [ 26456-59-7 ]

Physicochemical Properties

Num. heavy atoms :	7
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	24.05
TPSA :	46.01 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.23 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.67
Log Po/w (XLOGP3) :	-0.49
Log Po/w (WLOGP) :	0.18
Log Po/w (MLOGP) :	-1.13
Log Po/w (SILICOS-IT) :	0.62
Consensus Log Po/w :	-0.03

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-0.76
Solubility :	16.6 mg/ml ; 0.173 mol/l
Class :	Very soluble
Log S (Ali) :	-0.01
Solubility :	94.1 mg/ml ; 0.98 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.99
Solubility :	9.81 mg/ml ; 0.102 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.01

Safety of [ 26456-59-7 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 26456-59-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 26456-59-7 ]
Downstream synthetic route of [ 26456-59-7 ]

[ 26456-59-7 ] Synthesis Path-Upstream 1~4

1
[ 31458-33-0 ]
[ 26456-59-7 ]

Yield	Reaction Conditions	Operation in experiment
43%	Stage #1: at 150℃; sealed tube Stage #2: With acetic acid In methanol at 20℃;	A mixture of 77 (2.99 g, 27.2 mmol) and powdered potassium hydroxide (8.96 g of 85percent, 136 mmol) in methanol (50 mL) was heated in a sealed tube at 150° C. overnight. The mixture was cooled to room temperature, neutralized by the addition of acetic acid and concentrated under reduced pressure. The residue obtained was triturated with hot acetonitrile (2.x.100 mL) and the acetonitrile extracts concentrated under reduced pressure to afford 7.51 g of an off-white solid. This solid was triturated with hot ethyl acetate (100 mL) and the ethyl acetate extract concentrated under reduced pressure to afford 1.81 g of an off-white solid. Further purification by flash chromatography (silica, 9:1 methylene chloride/methanol) afforded 78 (1.11 g, 43percent) as an off-white solid: ¹H NMR (300 MHz, DMSO-d₆) δ 10.45 (br s, 1H), 8.67 (s, 1H), 8.34 (s, 2H).

Reference： [1] Chemistry - A European Journal, 2003, vol. 9, # 20, p. 4997 - 5010
[2] Patent: US2006/173049, 2006, A1, . Location in patent: Page/Page column 28-29
[3] Patent: WO2008/65393, 2008, A1, . Location in patent: Page/Page column 30
[4] Chemistry and Industry (London, United Kingdom), 1956, p. 1453
[5] Patent: US2002/143025, 2002, A1,
[6] Patent: US4127652, 1978, A,
[7] Patent: US2009/258876, 2009, A1, . Location in patent: Page/Page column 12
[8] Patent: EP2108649, 2009, A1, . Location in patent: Page/Page column 19
[9] Patent: US2012/214785, 2012, A1, . Location in patent: Page/Page column 47
[10] Patent: WO2009/125923, 2009, A2, . Location in patent: Page/Page column 33

2
[ 99984-35-7 ]
[ 26456-59-7 ]

Reference： [1] Patent: WO2012/37782, 2012, A1, . Location in patent: Page/Page column 58-59

3
[ 109299-78-7 ]
[ 26456-59-7 ]

Reference： [1] Journal of the American Chemical Society, [2] Journal of the American Chemical Society, 2009, vol. 131, p. 4174 - 4175

4
[ 1003015-89-1 ]
[ 14221-01-3 ]
[ 109299-78-7 ]
[ 26456-59-7 ]
[ 1134120-38-9 ]
[ 98511-61-6 ]

Reference： [1] Journal of the American Chemical Society, [2] Journal of the American Chemical Society, 2009, vol. 131, p. 4174 - 4175

[ 26456-59-7 ] Synthesis Path-Downstream 1~32

1
[ 31458-33-0 ]
[ 26456-59-7 ]

Yield	Reaction Conditions	Operation in experiment
43%		A mixture of 77 (2.99 g, 27.2 mmol) and powdered potassium hydroxide (8.96 g of 85%, 136 mmol) in methanol (50 mL) was heated in a sealed tube at 150 C. overnight. The mixture was cooled to room temperature, neutralized by the addition of acetic acid and concentrated under reduced pressure. The residue obtained was triturated with hot acetonitrile (2×100 mL) and the acetonitrile extracts concentrated under reduced pressure to afford 7.51 g of an off-white solid. This solid was triturated with hot ethyl acetate (100 mL) and the ethyl acetate extract concentrated under reduced pressure to afford 1.81 g of an off-white solid. Further purification by flash chromatography (silica, 9:1 methylene chloride/methanol) afforded 78 (1.11 g, 43%) as an off-white solid: 1H NMR (300 MHz, DMSO-d6) delta 10.45 (br s, 1H), 8.67 (s, 1H), 8.34 (s, 2H).
27%		Prepared as in Chem. Eur. J. 2003, 9, 4997-5010 on a 15 mmol scale with a yield of 27% after purification.1H NMR (DMSO^): delta 8.33 (s, 2H), 8.66 (s, IH), 10.45 (s, IH) ppm
	With 3-chloro-benzenecarboperoxoic acid; ethanethiol; In dichloromethane; ethyl acetate; N,N-dimethyl-formamide; mineral oil;	Preparation of 5-pyrimidinol In a three-necked flask cooled with ice is poured 3.38 g sodium hydride (3.38 g, 140.9 mmol) as a 60% suspension in mineral oil and dry DMF (60 ml). Ethanethiol (4.38 g, 70.48 mmol) is added dropwise and evolution of hydrogen is observed. After 15 minutes, 5-methoxypyrimidine (3.8 g, 35.3 mmol) is added and the resulting mixture is heated at 100 C. for 4 hours. A generous stream of argon is bubbled through during the reaction, and the head of the reflux condenser is connected with a cold trap charged with mCPBA in dichloromethane (in order to trap and oxidize the sulfide produced). The deep brown suspension is cooled with ice and the reaction is quenched with water (100 ml) neutralized with acetic acid and partitioned with ethyl acetate (4*100 ml). The organic layers are dried in vacuo and the residual yellow solid is purified by column chromatography using ethyl acetate as eluent. The compound is thus obtained as white needles. A yellow color is due to the presence of methyl-ethylsulfide and could be crystallized from dioxane to yield 1.7 g in 50% yield.

	With hydrogenchloride; potassium hydroxide; In methanol; ice-water; water;	EXAMPLE 1 The 5-hydroxy-pyrimidines (III) to be employed as starting materials could be prepared, for example, as follows: STR6 A solution of 49.5 g (0.45 mol) of 5-methoxypyrimidine [for its preparation see H. Bredereck et al., Chem. Ber. 91, (1958) page 2,848] and 38 g (0.68 mol) of potassium hydroxide in a mixture of 80 ml of water and 170 ml of methanol was heated for 3 hours to 190 C in an autoclave. The methanol was then distilled off, 50 ml of ice-water were added to the residue and the solution was brought to a pH value of 4.5 by adding concentrated hydrochloric acid while cooling. After 30 minutes, the product which had crystallized out was filtered off and 30 g (70% of theory) of 5-hydroxypyrimidine were thus obtained as a pale brown-colored crystal powder of melting point 208 C.
	With sodium hydride; ethanethiol; In N,N-dimethyl-formamide; at 100℃; for 4h;	NaH (0.91 g, 22.8 mmol) was dissolved in DMF (15 ml), ethanethiol (0.84 ml, 11.4 mmol) was added to the solution, and the mixture was stirred at room temperature for 30 min. 5-methoxy pyrimidine (628 mg, 5.65 mmol) was added to the mixture and stirred at 100 C. for 4 hours. Subsequently, the product was filtered, washed, and dried to prepare pyrimidine-5-ol (681 mg, 5.65 mmol).
	With sodium hydride; ethanethiol; In N,N-dimethyl-formamide; at 20 - 100℃;	NaH (0.91 g, 22.8 mmol) was dissolved in DMF (15 m), ethanethiol (0.84 m, 11.4 mmol) was added to the solution, and the mixture was stirred at room temperature for 30 min. 5-methoxy pyrimidine (628 mg, 5.65 mmol) was added to the mixture and stirred at 100 Cfor 4 hours. Subsequently, the product was filtered, washed, and dried to prepare pyrimidine-5-ol (681 mg, 5.65 mmol).
		b An autoclave is charged with 13.1 g (119 mmol) 5-methoxy-pyrimidine and 250 ml Methanol. 66.8 g (1.19 mol) KOH are added and the mixture is stirred at 125 C. over night. After this the mixture is neutralized with AcOH to pH 6-7 and then concentrated under vacuo. The residue is triturated four times with hot MeCN and the combined extracts are concentrated under vacuum. The resulting crude product is purified by flash chromatography (EtOAc 100%). C4H4N2O (M=96.09 g/mol) ESI-MS: 95 [M-H]-
	With sodium hydride; ethanethiol; In N,N-dimethyl-formamide; at 100℃; for 4h;	NaH (0.91 g, 22.8 mmol) was dissolved in DMF (15 ), ethanethiol (0.84 , 11.4 mmol) was added to the solution, and the mixture was stirred at room temperature for 30 min. 5-methoxy pyrimidine (628 , 5.65 mmol) was added to the mixture and stirred at 100 for 4 hours. Subsequently, the product was filtered, washed, and dried to prepare pyrimidine-5-ol (681 , 5.65 mmol).

Reference： [1]Chemistry - A European Journal,2003,vol. 9,p. 4997 - 5010
[2]Patent: US2006/173049,2006,A1 .Location in patent: Page/Page column 28-29
[3]Patent: WO2008/65393,2008,A1 .Location in patent: Page/Page column 30
[4]Chemistry and industry,1956,p. 1453
[5]Patent: US2002/143025,2002,A1
[6]Patent: US4127652,1978,A
[7]Patent: US2009/258876,2009,A1 .Location in patent: Page/Page column 12
[8]Patent: EP2108649,2009,A1 .Location in patent: Page/Page column 19
[9]Patent: US2012/214785,2012,A1 .Location in patent: Page/Page column 47
[10]Patent: WO2009/125923,2009,A2 .Location in patent: Page/Page column 33

2
[ 110-91-8 ]
[ 26456-59-7 ]
[ 50-00-0 ]
[ 82040-05-9 ]

Reference： [1]Chemistry of Heterocyclic Compounds,1982,vol. 18,p. 297 - 299
Khimiya Geterotsiklicheskikh Soedinenii,1982,vol. 18,p. 393 - 396

3
[ 26456-59-7 ]
[ 51-80-9 ]
[ 82040-04-8 ]

Reference： [1]Chemistry of Heterocyclic Compounds,1982,vol. 18,p. 297 - 299
Khimiya Geterotsiklicheskikh Soedinenii,1982,vol. 18,p. 393 - 396

4
[ 26456-59-7 ]
[ 100-05-0 ]
[ 82040-08-2 ]

Reference： [1]Chemistry of Heterocyclic Compounds,1982,vol. 18,p. 297 - 299
Khimiya Geterotsiklicheskikh Soedinenii,1982,vol. 18,p. 393 - 396

5
[ 26456-59-7 ]
[ 88070-44-4 ]

Reference： [1]Chemistry of Heterocyclic Compounds,1983,vol. 19,p. 1003 - 1007
Khimiya Geterotsiklicheskikh Soedinenii,1983,p. 1252 - 1256

6
[ 26456-59-7 ]
[ 126126-56-5 ]

Reference： [1]Chemical and pharmaceutical bulletin,1989,vol. 37,p. 1984 - 1986

9
[ 26456-59-7 ]
[ 1943-83-5 ]
carbamic acid, (2-chloroethyl)-5-pyrimidine ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2000,vol. 43,p. 1484 - 1488

10
[ 26456-59-7 ]
5-pyrimidinoxyl radical [ No CAS ]

Reference： [1]Chemistry - A European Journal,2003,vol. 9,p. 4997 - 5010

11
[ 26456-59-7 ]
[ 403-42-9 ]
[ 904686-27-7 ]

Yield	Reaction Conditions	Operation in experiment
38%	With potassium carbonate; In ISOPROPYLAMIDE; at 120℃;	A mixture of 4'-fluoroacetophenone (0.36 g, 2.60 mmol), 78 (0.25 g, 2.60 mmol) and potassium carbonate (0.43 g, 3.12 mmol) in dimethylacetamide (2.5 mL) was heated at 120 C. overnight. The mixture was cooled to room temperature and diluted with water (25 mL) and ethyl acetate (25 mL). The organic layer was separated, washed with brine (25 mL), dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography (silica, 1:1 ethyl acetate/hexanes) afforded 79 (0.21 g, 38%) as a white solid: 1H NMR (300 MHz, CDCl3) delta 9.07 (s, 1H), 8.56 (s, 2H), 8.02 (dd, J=6.9, 1.8 Hz, 2H), 7.09 (dd, J=6.9, 1.8 Hz, 2H), 2.63 (s, 3H); ESI MS m/z 215 [C12H10N2O2+H]+.

Reference： [1]Patent: US2006/173049,2006,A1 .Location in patent: Page/Page column 28-29
[2]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 2068 - 2073

Yield	Reaction Conditions	Operation in experiment
		4,6-dimethyl-5-pyrimidinol and 2,4,6-trimethyl-5-pyrimidinol are prepared according to the method of A. Dornow and H. Hell, Chem. Ber. 93, 1998-2001 (1960), in which 3-chloro-2,4-pentanedione are reacted with formamide or acetamide to give the corresponding oxazole which is heated with ammona under pressure to give the desired 5-pyrimidinol.

13
[ 26456-59-7 ]
[ 459-57-4 ]
[ 1030379-80-6 ]

Yield	Reaction Conditions	Operation in experiment
43%	With sodium methansulfinate; potassium carbonate; In N,N-dimethyl-formamide; at 120℃; for 3h;	To a stirred solution of <strong>[26456-59-7]pyrimidin-5-ol</strong> (0.384 g, 4.0 mmol) in DMF (4.0 mL) were added 4-fluorobenzaldehyde (0.429 g, 4.0 mmol), sodium methanesulphinate (0.118 g, 1.0 mmol) and potassium carbonate (0.828 g, 6.0 mmol). The reaction mixture was heated at 120 0C o for 3 hours, cooled to ambient temperature, treated with water and extracted three times with TBME. The extracts were washed with brine, dried and concentrated. Column chromatography gave 0.523 g (43%) of the subtitle compound. APCI-MS m/z: 201 (M+l).1H NMR (CDCl3): delta 7.15 (dd, 2H), 7.93 (dt, 2H), 8.58 (s, 2H), 9.13 (s, IH), 9.98 (s, IH) s ppm.

Reference： [1]Patent: WO2008/65393,2008,A1 .Location in patent: Page/Page column 30

14
[ 26456-59-7 ]
[ 4548-45-2 ]
[ 287944-18-7 ]

Yield	Reaction Conditions	Operation in experiment
87%	With sodium hydride; In N,N-dimethyl-formamide; at 20℃; for 1h;	Pyrimidine-5-ol (0.39 g, 4.02 mmol) was dissolved in DMF (10 ml), and the solution was stirred with NaH (210 mg, 5.23 mmol) and 2-chloro-5-nitro pyridine (0.64 g, 4.04 mmol) at room temperature for 1 hour. Subsequently, the product was filtered, washed, and dried under reduced pressures to yield a solid product (0.77 g, 87%). The solid product (0.2 g, 0.92 mmol) was added to a mixed solution of ethanol (7 ml) and conc. hydrochloric acid (2 ml), SnCl2 (0.72 g, 3.22 mmol) was added to the mixture, and the resulting solution was stirred at 60 C. for 1 hour. And then the product was filtered, washed, and dried to prepare 6-(pyrimidine-5-yloxy)-pyridine-3-ylamine (0.17 g, 96%).
87%	With sodium hydride; In N,N-dimethyl-formamide; at 20℃; for 1h;	Pyrimidine-5-ol (0.39 g, 4.02 mmol) was dissolved in DMF (10 m), and the solution was stirred with NaH (210 mg, 5.23 mmol) and 2-chloro-5-nitro pyridine (0.64 g, 4.04 mmol) at room temperature for 1 hour. Subsequently, the product was filtered, washed, and dried under reduced pressures to yield a solid product (0.77 g, 87 %).
87%	With sodium hydride; In N,N-dimethyl-formamide; at 20℃; for 1h;	Pyrimidine-5-ol (0.39 g, 4.02 mmol) was dissolved in DMF (10 ), and the solution was stirred with NaH (210 , 5.23 mmol) and 2-chloro-5-nitro pyridine (0.64 g, 4.04 mmol) at room temperature for 1 hour. Subsequently, the product was filtered, washed, and dried under reduced pressures to yield a solid product (0.77 g, 87 %).

Reference： [1]Patent: US2009/258876,2009,A1 .Location in patent: Page/Page column 12
[2]Patent: EP2108649,2009,A1 .Location in patent: Page/Page column 19
[3]Patent: WO2009/125923,2009,A2 .Location in patent: Page/Page column 33
[4]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 3844 - 3847

15
[ 1003015-89-1 ]
[ 14221-01-3 ]
[ 109299-78-7 ]
[ 26456-59-7 ]
[ 1134120-38-9 ]
[ 98511-61-6 ]

Reference： [1]Journal of the American Chemical Society,2009,vol. 131,p. 4174 - 4175

16
[ 109299-78-7 ]
[ 26456-59-7 ]

Reference： [1]Journal of the American Chemical Society,2009,vol. 131,p. 4174 - 4175

17
[ 26456-59-7 ]
[ 15540-81-5 ]
[ 1352834-82-2 ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate;2,2,6,6-tetramethylheptane-3,5-dione; copper(l) chloride; In 1-methyl-pyrrolidin-2-one; at 130℃;Sealed tube;	5-(2,5-Dimethyl-4-nitrophenoxy)pyrimidine; A solution of l-bromo-2,5-dimethyl-4-nitrobenzene (3.53 g, 15.34 mmol), pyrimidin-5-ol (1.474 g, 15.34 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (0.141 g, 0.767 mmol), cesium carbonate (5.15 g, 15.80 mmol) and copper(I) chloride (0.410 g, 4.14 mmol) in N-methyl-2-pyrrolidinone (15.34 mL) was heated in a sealed pressure tube at 130 C and stirred overnight. The reaction was cooled to room temperature, diluted with EtOAc and washed with water (2x) and brine, successively, dried over Na2SO4, filtered and concentrated in vacuo. This was triturated with diethyl ether to give the first crop of the desired product (1.682 g) as a light tan solid. The filtrate was concentrated in vacuo, and the residue was purified by flash chromatography using an ISCO 80g column eluting with 0-50%EtOAc/hexanes. Appropriate fractions were collected and concentrated in vacuo to give the second crop of the desired product (0.3973 g) as an off- white solid.

Reference： [1]Patent: WO2011/159857,2011,A1 .Location in patent: Page/Page column 68-69

18
[ 99984-35-7 ]
[ 26456-59-7 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogen;palladium 10% on activated carbon; In methanol; at 20℃;	D136 pyrimidin-5-ol To a solution of 5-[(phenylmethyl)oxy]pyrimidine (2.43 g, 13.0 mmol) in methanol (20 mL) was added Pd/C (10 % Pd/C, 10 % on carbon). The reaction mixture was stirred at room temperature under H2 atmosphere over weekend, then filtered and concentrated. The residue was used into next step without purification.

Reference： [1]Patent: WO2012/37782,2012,A1 .Location in patent: Page/Page column 58-59

19
[ 26456-59-7 ]
[ 22282-70-8 ]
[ 1353776-68-7 ]

Yield	Reaction Conditions	Operation in experiment
		Example IX.1 5-(4-Iodo-pyridin-2-yloxy)-pyrimidine To 259 mg (26.9 mmol) <strong>[26456-59-7]pyrimidin-5-ol</strong> (J. Chem. Soc. 1956, 2033) in 200 mL DMF are added 108 mg (26.9 mmol) sodium hydride (60% dispersion in mineral oil). The mixture is stirred for 20 min at rt. After that time, 500 mg (22.4 mmol) 2-fluoro-4-iodopyridine are added and the mixture is stirred for 12 h at 80 C. Subsequently the mixture is poured into water and extracted with ethyl acetate (3*). The combined organic layers are washed with brine. After drying over sodium sulphate, the solvent is removed in vacuo and the residue is purified by column chromatography (silica gel; heptane/ethyl acetate, gradient 0-60%) to yield the desired product. C9H61N3O (M=299.1 g/mol), ESI-MS: 300 [M+H]+
		To 259 mg (26.9 mmol) <strong>[26456-59-7]pyrimidin-5-ol</strong> (J. Chem. Soc. 1956, 2033) in 200 mL DMF are added 108 mg (26.9 mmol) sodium hydride (60% dispersion in mineral oil). The mixture is stirred for 20 mm at r.t.. After that time, 500 mg (22.4 mmol) 2-fluoro-4-iodopyridine are added and the mixture is stirred for 12 h at 80 C. Subsequently the mixture is poured into water and extracted with ethyl acetate (3x). The combined organic layers are washed with brine. After drying over sodium sulphate, the solvent is removed in vacuo and the residue is purified by column chromatography (silica gel; heptane/EtOAc, 100/0 - 40/60).C9H6IN3O (M = 299.1 g/mol)ESI-MS: 300 [M+H]+ Rt(HPLC) : 2.87 mm (method C)
		Example XXVIII.1 (General Route) 5-(4-Iodo-pyridin-2-yloxy)-pyrimidine To 259 mg (26.9 mmol) <strong>[26456-59-7]pyrimidin-5-ol</strong> (J. Chem. Soc. 1956, 2033) in 200 mL DMF are added 108 mg (26.9 mmol) sodium hydride (60% dispersion in mineral oil). The mixture is stirred for 20 min at r.t. After that time, 500 mg (22.4 mmol) 2-fluoro-4-iodopyridine are added and the mixture is stirred for 12 h at 80 0. Subsequently the mixture is poured into water and extracted with ethyl acetate (3*). The combined organic layers are washed with brine. After drying over sodium sulphate, the solvent is removed in vacuo and the residue is purified by column chromatography (silica gel; heptane/EtOAc, 100/0?40/60). C9H6IN3O (M=299.1 g/mol) ESI-MS: 300 [M+H]+Rt (HPLC): 2.87 min (method C)

Reference： [1]Patent: US2012/157425,2012,A1 .Location in patent: Page/Page column 47-48
[2]Patent: WO2013/92616,2013,A1 .Location in patent: Page/Page column 93
[3]Patent: US2013/158004,2013,A1 .Location in patent: Paragraph 0565; 0566; 0567; 0568; 0569

20
[ 26456-59-7 ]
[ 104711-65-1 ]
[ 1396337-93-1 ]

Yield	Reaction Conditions	Operation in experiment
82.1%	With potassium carbonate; In N,N-dimethyl-formamide; at 25 - 80℃; for 36h;Large scale;	To a solution of 5-hydroxypyrimidine (9, 1.73 kg, 18.08 mol) in DMF (23.0 L,10 V), potassium carbonate (6.25 kg, 45.21 mol) was added followed by <strong>[104711-65-1]4-chloro-6-methylpicolinonitrile</strong> (8, 2.3 kg, 15.07 mol) at 25-30 C. The reactionmass was heated at 75-80 C for 36 h. The reaction was monitored by HPLC 8NMT 2.0% by HPLC). Reaction mass was cooled to 25-30 C. The solid wasfiltered and washed the solid with DMF (4.6 L, 2.0 V). The filtrate was cooled to0-5 C and purified water (27.6 L, 12 V) was added drop wise over a period of1 h. The solid precipitated was filtered and washed with purified water (2.3 L,10 V) to afford 10 as off white solid (2.62 kg, 82.1%). 1H NMR (400 MHz, DMSOd6)d 9.17 (s, 1H), 8.85 (s, 2H), 7.74 (d, J = 2.4 Hz, 1H), 7.32 (d, J = 2.3 Hz, 1H),2.48 (s, 3H); 13C NMR (100 MHz, DMSO-d6) d = 164.04, 162.28, 155.51, 150.02,148.75, 133.54, 117.05, 115.59, 115.04, 23.82 ppm; LCMS (Method 1):RT = 0.535 min, m/z = 213.2 [M+H]+; HRMS, calc?d for C11H8N4O [M],212.0698; found 212.0697.
77%	With potassium carbonate; In N,N-dimethyl-formamide; at 80℃; for 16h;	d. PREPARATION OF 6-METHYL-4-(PYRIMIDIN-5-YLOXY)PICOLINONITRILE.[00399] <strong>[104711-65-1]4-chloro-6-methylpicolinonitrile</strong> (4.0 g, 26 mmol, 1.0 eq), 5-hydroxypyrimidine (5.56 g, 57.9 mmol, 2.20 eq), K2C03 (7.24 mg, 52.4 mmol, 2.0 eq) and DMF (66 mL) were added to a reaction vessel and heated at 80 C for 16 hours. The reaction was filtered and concentrated on silica gel (25 g). The silica gel was loaded on top of a fresh bed of silica gel and washed with 50% ethyl acetate/hexane. The solvents were removed in vacuo and the crude solid was purified by flash chromatography on silica gel to afford 4.31 g (77%) of the title compound as a pale-yellow solid. NMR (400 MHz, DMSO-<¾) delta 9.1 7 (s, 1 H), 8.85 (s, 2H), 7.74 (d, J = 2.4 Hz, 1 H), 7.32 (d, J = 2.3 Hz, 1 H), 2.48 (s, 3H); ES-MS [M+l ]+: 213.2.

Reference： [1]Tetrahedron Letters,2017,vol. 58,p. 3554 - 3558
[2]Patent: WO2012/118563,2012,A2 .Location in patent: Page/Page column 136
[3]Journal of Medicinal Chemistry,2017,vol. 60,p. 5072 - 5085

21
[ 26456-59-7 ]
C₁₅H₁₈ClN₅O [ No CAS ]
C₁₉H₂₁N₇O₂ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1529 - 1536

22
[ 26456-59-7 ]
[ 1425310-30-0 ]
[ 1425310-32-2 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1529 - 1536

23
[ 26456-59-7 ]
[ 407-20-5 ]
[ 1279461-93-6 ]

Yield	Reaction Conditions	Operation in experiment
92%	With potassium carbonate; In N,N-dimethyl-formamide; at 200℃; for 30h;	3. ROUTE IIIa. 5-((5-BROMOPYRIDIN-3-YL)OXY)PYRIMIDINE (5). [00316] A mixture of 3-bromo-5-fluoropyridine (2.0 g, 11 mmol, 1.0 eq), 5- hydroxypyrimidine (1.3 g, 14 mmol, 1.2 eq), and potassium carbonate (2.4 g, 17 mmol, 1.5 eq) in DMF (40 mL) was microwaved at 200C for 30 minutes. The reaction was diluted with 3M LiCl and extracted (3x) with CH2C12. The combined organics were dried (MgS04), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 1.7 g (92%) of the title compound as a tan solid: 1H NMR (400 MHz, DMSO-<¾) delta 9.07 (s, 1H), 8.77 (s, 2H), 8.58 (d, J= 1.8 Hz, 1H), 8.54 (d, J= 2.4 Hz, 1H), 8.02 (t, J= 2.1 Hz, 1H); ES-MS [M+l]+:252.0.

Reference： [1]Patent: WO2011/35174,2011,A1 .Location in patent: Page/Page column 139-140

24
[ 26456-59-7 ]
[ 64248-63-1 ]
[ 1276619-83-0 ]

Yield	Reaction Conditions	Operation in experiment
48%	With potassium carbonate; In N,N-dimethyl-formamide; at 150℃; for 0.25h;	(a) 3,5-difluorobenzonitrile (1.0 g, 7.2 mmol,1.0 equiv), <strong>[26456-59-7]5-hydroxypyrimidine</strong> (691 mg, 7.19 mmol, 1.0 equiv), K2CO3 (1.2 g,8.7 mmol, 1.2 equiv) and DMF (17 mL) were added to a microwave vial and heated at 150 C for 15 min. The reaction was filtered and concentrated on silica gel. The silica gel with absorbed compound was loaded on top a fresh pad of silica gel and washed with 50% ethyl acetate/hexane. The solvents were removed in vacuo and the crude mixture was purified by flash chromatography on silica gel to afford 750 mg (48%) of the desired compound.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 5779 - 5785

25
[ 26456-59-7 ]
[ 4774-14-5 ]
[ 1620203-22-6 ]

Yield	Reaction Conditions	Operation in experiment
51%	With potassium carbonate; In N,N-dimethyl-formamide; at 120℃; for 0.166667h;	A mixture of 2,6-dichloropyrazine (1.00g, 6.71mmol, 1.00equiv), <strong>[26456-59-7]pyrimidin-5-ol</strong> (645mg, 6.71mmol, 1.00equiv), and potassium carbonate (1.39g, 10.1mmol, 1.50equiv) in DMF (20mL) was heated via microwave irradiation at 120C for 10min. The reaction was cooled and diluted with EtOAc and washed with H2O (3×) and brine (1×). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 710mg (51%) of the title compound. 1H NMR (400MHz, DMSO-d6) delta 9.15 (s, 1H), 8.93 (s, 2H), 8.73 (s, 1H), 8.62 (s, 1H); ES-MS [M+H]+: 209.1.

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 3307 - 3314

26
[ 26456-59-7 ]
[ 1033589-08-0 ]
6-((1-(2-(2-oxo-7-(pyrimidin-5-yloxy)-1,8-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2015,vol. 6,p. 741 - 746

27
[ 26456-59-7 ]
[ 16420-13-6 ]
S-pyrimidin-5-yl N,N-dimethylcarbamothioate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
11%		S-pyrimidin-5- l N,N-dimethylcarbamothioate 15 (used during synthesis of 20) (I5) (a) Dimethyl-thiocarbamic acid pyrimidin-5-yl ester NaH (60% dispersion, 450 mg, 11.25 mmol) was added to <strong>[26456-59-7]5-hydroxypyrimidine</strong> (1.03 g, 10.72 mmol) in dry DMF (10 mL) at rt. The reaction mixture was stirred for 10 min, then Nu,Nu-dimethylthiocarbamoyl chloride (1.39 g, 11.25 mmol) was added. The reaction mixture was heated to 90 C for 1 h, then stirred at rt for 18 h. The reaction mixture was poured into brine (40 mL) and was extracted with DCM (3 x 30 mL). The combined organic extracts were passed through a phase separator cartridge and the solvent removed in vacuo to give the crude product which was purified by flash column chromatography (Biotage Isolera 4) eluting with neat iso-hexane to 50% EtOAc / iso- hexane to give the title compound as a yellow solid (212 mg, 1.16 mmol, 1 1 %).

Reference： [1]Patent: WO2015/181551,2015,A1 .Location in patent: Page/Page column 36

28
[ 26456-59-7 ]
[ 19235-89-3 ]
C₁₀H₆N₄O [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 5072 - 5085

29
[ 26456-59-7 ]
C₇H₃ClF₂N₂ [ No CAS ]
C₁₁H₆F₂N₄O [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 5072 - 5085

30
[ 26456-59-7 ]
[ 1258544-91-0 ]
C₉H₅BrN₄O₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃; for 4h;	General procedure: Compound 6 (1.16g, 5.35mmol), 3-fluoro-5-hydroxypyridine (712mg, 6.30mmol), potassium carbonate (1.45g, 10.5mmol) and DMF (13mL) were added to a round-bottom flask and stirred at rt for 4h. The reaction was filtered and washed with ethyl acetate. The filtrate was washed with water (2×), and the aqueous layer was extracted with ethyl acetate. The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash chromatography on silica gel afforded 1.50g (91%) of the title compound as a light brown solid

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2017,vol. 27,p. 4858 - 4866

31
[ 26456-59-7 ]
[ 1445993-88-3 ]
C₁₈H₁₃N₅O₄ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 8369 - 8384

32
[ 26456-59-7 ]
7-(4-fluorophenyl)-2-(hydroxymethyl)thieno[3,2-b]pyridine-5-carbonitrile [ No CAS ]
C₁₉H₁₁FN₄OS [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2019,vol. 62,p. 378 - 384

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 26456-59-7 ]

Alcohols

[ 143489-45-6 ]

2-Aminopyrimidin-5-ol

Similarity: 0.85

[ 35231-56-2 ]

2-Methylpyrimidin-5-ol

Similarity: 0.83

[ 52601-89-5 ]

4-Aminopyrimidin-5-ol

Similarity: 0.83

[ 1240621-87-7 ]

2-Bromo-5-hydroxypyrimidine

Similarity: 0.80

[ 4983-28-2 ]

2-Chloro-5-hydroxypyrimidine

Similarity: 0.78

Related Parent Nucleus of
[ 26456-59-7 ]

Pyrimidines

[ 143489-45-6 ]

2-Aminopyrimidin-5-ol

Similarity: 0.85

[ 35231-56-2 ]

2-Methylpyrimidin-5-ol

Similarity: 0.83

[ 52601-89-5 ]

4-Aminopyrimidin-5-ol

Similarity: 0.83

[ 1240621-87-7 ]

2-Bromo-5-hydroxypyrimidine

Similarity: 0.80

[ 4983-28-2 ]

2-Chloro-5-hydroxypyrimidine

Similarity: 0.78

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 26456-59-7 ] {[proInfo.proName]}

Quality Control of [ 26456-59-7 ]

Related Doc. of [ 26456-59-7 ]

Product Details of [ 26456-59-7 ]

Calculated chemistry of [ 26456-59-7 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 26456-59-7 ]

Application In Synthesis of [ 26456-59-7 ]

[ 26456-59-7 ] Synthesis Path-Upstream 1~4

[ 26456-59-7 ] Synthesis Path-Downstream 1~32

Related Functional Groups of [ 26456-59-7 ]

Alcohols

Related Parent Nucleus of [ 26456-59-7 ]

Pyrimidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 26456-59-7 ]

Related Parent Nucleus of
[ 26456-59-7 ]